Results 11 to 20 of about 192,819 (168)

Cannabis-opioid interaction in the treatment of fibromyalgia pain: an open-label, proof of concept study with randomization between treatment groups: cannabis, oxycodone or cannabis/oxycodone combination—the SPIRAL study

Trials, 2023
Background Opioids continue to be widely prescribed for chronic noncancer pain, despite the awareness that opioids provide only short-time pain relief, lead to dose accumulation, have numerous adverse effects, and are difficult to wean. As an alternative,
Cornelis Jan van Dam, Monique van Velzen, Cornelis Kramers, Arnt Schellekens, Erik Olofsen, Marieke Niesters, Albert Dahan   +6 more
doaj   +1 more source

Extension for Community Healthcare Outcomes (ECHO) Chronic Pain & Opioid Stewardship in Northwestern Ontario: A Thematic Analysis of Patient Cases

Canadian Journal of Pain, 2022
Background Chronic pain (CP) is a debilitating disease that reduces quality of life, decreases productivity, and has become a primary cause of health care resource consumption.
Patricia A. Poulin, Yaadwinder Shergill, Adrian Grebowicz, Inês Almeida, Rosemee Cantave, Bryan MacLeod, Tim Larocque, Donna Garstin, Sarah F. Fitzgerald, Joshua A. Rash   +9 more
doaj   +1 more source

HealthCare educational differences in pain management, adverse childhood experiences and their relationship to substance use disorder education

Substance Abuse Treatment, Prevention, and Policy, 2022
Background In order to assist the State of Ohio in the United States in addressing the opioid epidemic, the Ohio Attorney General appointed experts in a variety of academic disciplines to the Scientific Committee on Opioid Prevention and Education (SCOPE)
Myriam Shaw Ojeda, Aleda M. H. Chen, Tessa Miracle, Elizabeth Delaney, Caroline E. Freiermuth, Jon E. Sprague   +5 more
doaj   +1 more source

Impact of Chronic Alcohol and Opioid Dependence on Biochemical Parameters: A Retrospective Case Control Study from a Tertiary Care Treatment Center in North India [PDF]

Addiction and Health, 2021
Background: Assessment of biochemical parameters can help in the comprehensive management of patients with substance use disorders (SUDs). The aim of this study was to analyse the biochemical parameters of patients with alcohol and opioid dependence at ...
Rizwana Quraishi, Siddharth Sarkar, Raka Jain   +2 more
doaj   +1 more source

Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs

Substance Abuse Treatment, Prevention, and Policy, 2023
Background Medications for opioid use disorder (MOUD; methadone, buprenorphine, naltrexone) are the most effective treatments for OUD, and MOUD is protective against fatal overdoses.
Jaclyn M. W. Hughto, Abigail Tapper, Sabrina S. Rapisarda, Thomas J. Stopka, Wilson R. Palacios, Patricia Case, Joseph Silcox, Patience Moyo, Traci C. Green   +8 more
doaj   +1 more source

Alternatives to Arrest for Illicit Opioid Use: A Joint Criminal Justice and Healthcare Treatment Collaboration

Substance Abuse: Research and Treatment, 2020
Opioid overdoses continue to be a leading cause of death in the US. This public health crisis warrants innovative responses to help prevent fatal overdose.
Andrea J Yatsco, Rachel D Garza, Tiffany Champagne-Langabeer, James R Langabeer   +3 more
doaj   +1 more source

The Opioid-Tolerant Patient: Opioid Optimization [PDF]

The Journal of Arthroplasty, 2020
Chronic opioid use and abuse continue to plague our country despite efforts to curtail their use. Patients on chronic opioids (opioids tolerant) who undergo total joint arthroplasty have been clearly shown to have higher rates of complications, infection, and early revision compared to the opioid-naïve patients.
Padma, Gulur, Amanda H, Nelli
openaire   +2 more sources

Naltrexone beyond Psychiatric Domain

Indian Journal of Medical Specialities, 2022
Naltrexone, an opioid receptor (OR) antagonist, at its standard doses, is a United States Federal Drug Administration-approved drug for opioid and alcohol use disorders.
Ashutosh Garg, Khyati Thapliyal, Vivek Pal Singh   +2 more
doaj   +1 more source

Opioid suppression of an excitatory pontomedullary respiratory circuit by convergent mechanisms

eLife, 2023
Opioids depress breathing by inhibition of interconnected respiratory nuclei in the pons and medulla. Mu opioid receptor (MOR) agonists directly hyperpolarize a population of neurons in the dorsolateral pons, particularly the Kölliker-Fuse (KF) nucleus ...
Jordan T Bateman, Erica S Levitt
doaj   +1 more source

Plasma Pro‐Enkephalin A and Incident Cognitive Impairment: The Reasons for Geographic and Racial Differences in Stroke Cohort

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Cardiovascular disease is a risk factor for cognitive impairment. Evidence links both lower and higher concentration of the circulating opioid pro‐enkephalin A (PENK‐A) with stroke risk.
Samuel A. P. Short, Katherine Wilkinson, Janin Schulte, Miguel Arce Renteria, Katharine L. Cheung, Charles D. Nicoli, Virginia J. Howard, Mary Cushman   +7 more
doaj   +1 more source